In light of the TRIANGLE data at ASH, how should we now approach a transplant-eligible patient with a new diagnosis of aggressive mantle cell lymphoma?

The TRIANGLE data presented by Dr. Dreyling on behalf of the European Mantle Cell Network are certainly provocative. Adding ibrutinib to induction pre-BEAM and maintenance post-BEAM (A+I) led to improved FFS compared to standard-of-care induction and maintenance (A). Not surprising, and doesn't tell...

The TRIANGLE study was a monumental trial led by the European MCL network. The study evaluated three arms R-CHOP/R-DHAP followed by ASCT, R-CHOP/R-DHAP + Ibrutinib (I) followed by ASCT + I (2 years), and R-CHOP/R-DHAP + I followed by I (2 years).

The study demonstrated that the I-containing arms had...